Refactor Capital

Refactor Capital is an early-stage venture firm whose name has historically signaled a focus on rebuilding industries that have resisted software, with biology and healthcare among the recurring themes in its portfolio. Public data here is thin, but the firm’s positioning suggests seed and Series A checks into companies attempting structural change in markets like life sciences tools, food and biology, financial infrastructure, and other regulated verticals. For healthcare AI founders, the relevant question is whether your company is genuinely refactoring a workflow or category rather than layering AI on top of an existing one. Companies bringing computational approaches to drug discovery, clinical operations, or diagnostics that previously relied on manual labor are the type of bet that fits the brand. Check sizes at this tier of firm typically range from several hundred thousand dollars on a seed party round to a couple of million as a meaningful seed lead, with follow-on reserves attached. Founders should not approach Refactor expecting a generalist software pitch to land. The better entry path is a warm introduction from a portfolio founder or an operator the partners trust, paired with a thesis-led note that explicitly frames why the incumbent stack is broken and how your approach restructures the economics. Cold outbound through the website or LinkedIn is unlikely to clear the bar without a strong referral. Treat this firm as a thoughtful early-stage partner for ambitious technical founders, and budget for a longer diligence cycle in which the partners will pressure-test scientific or clinical claims rather than rubber-stamp a deck.